Clinical trials: Bladder
Overactive Bladder
A Confirmatory Study of KUC-7483 in Patients With Overactive Bladder
To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.
- Trial name
- NCT01004315
- Testing
- KUC-7483, Tolterodine
- Where
- Japan
- Volunteers
- 750 people
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
Bladder Cancer
Study of Mycobacterium w in Superficial Transitional Cell Carcinoma of Bladder
The purpose of this study is to determine and compare the effect of this treatment on recurrence rate and to assess the toxicity in both arms of patients with STCC.
- Trial name
- STCC (NCT00694915)
- Testing
- Mycobacterium w, BCG (Bacillus Calmette-Guerin)
- Where
- 15 sites in India
- Volunteers
- 122 people
- Sponsor
- Cadila Pharnmaceuticals
Muscle-Invasive Bladder Carcinoma, Metastatic Urothelial Carcinoma
Modular Trial of sEphB4-HSA in EphrinB2-High Solid Tumors
Patients with solid tumors that have high expression levels of EphrinB2 are treated with regimens that include EphrinB2 inhibitor, sEphB4-HSA.
- Trial name
- NCT06493552
- Testing
- SEphB4-HSA, Pembrolizumab, Gemcitabine
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Vasgene Therapeutics, Inc
Overactive Bladder, Urinary Incontinence
A Study of Solifenacin With Bladder Training Versus Solifenacin Alone in Patients With Overactive Bladder (SOLAR)
This study will look at a drug for OAB (solifenacin) in combination with a non drug treatment (bladder training) compared to the drug on its own.
- Conditions
- Overactive Bladder, Urinary Incontinence, Urge Incontinence
- Trial name
- SOLAR (NCT00337558)
- Testing
- Solifenacin succinate, Simplified bladder training
- Where
- 64 sites in Australia, Belgium and 9 more
- Volunteers
- 643 people
- Sponsor
- Astellas Pharma Inc
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Trial name
- NCT00005958
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- 12 sites in United States
- Sponsor
- Amgen
Bladder Cancer
Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit
The purpose of this study is to see if the Neo-Urinary Conduit(NUC), which is made in the laboratory from a combination of a patient's own cells and other materials can be used to form a conduit to safety allow urine flow from…
- Trial name
- NCT01087697
- Testing
- Neo-Urinary Conduit
- Where
- 6 sites in United States
- Volunteers
- 8 people
- Sponsor
- Tengion
Ovarian Cancer, Hepatocellular Carcinoma
Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors
This study will assess the safety and efficacy of DPX-Survivac and low dose cyclophosphamide with pembrolizumab in subjects with selected advanced and recurrent solid tumours.
- Conditions
- Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer
- Trial name
- NCT03836352
- Testing
- DPX-Survivac, Cyclophosphamide, Pembrolizumab
- Where
- 23 sites in United States, Canada
- Volunteers
- 184 people
- Sponsor
- ImmunoVaccine Technologies, Inc. (IMV Inc.)
Detrusor Function, Overactive
Extended-Release Oxybutynin for the Treatment of Neurogenic Detrusor Overactivity
The purpose of this study is to evaluate the effects and tolerability (how well a participant can stand a particular medicine or treatment) of flexible dose Oxybutynin Extended-Release (OXY-ER, Lyrinel) including safety and…
- Trial name
- RONDO (NCT01796548)
- Testing
- Oxybutinin Extended-Release
- Where
- 3 sites in Thailand
- Volunteers
- 17 people
- Sponsor
- Janssen-Cilag Ltd.,Thailand
Relapsing-Remitting Multiple Sclerosis
A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function
The primary objective of the study was to measure the change in bladder function as measured by Urogenital Distress Inventory (UDI)-6 compared to baseline over 6 months of Tysabri treatment.
- Trial name
- TRUST (NCT00818038)
- Testing
- BG0002 (natalizumab)
- Volunteers
- 30 people
- Sponsor
- Biogen
Overactive Bladder
Long Term Study To Evaluate the Safety, Tolerability and Efficacy of Fesoterodine for Overactive Bladder.
To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.
- Trial name
- NCT00658684
- Testing
- fesoterodine fumarate
- Where
- 12 sites in Japan
- Volunteers
- 153 people
- Sponsor
- Pfizer
Over Active Bladder
BlueWind Medical System for the Treatment of Patients With OAB
BlueWind system safety and performance in treatment of patients diagnosed with overactive bladder (OAB)
- Trial name
- OAB (NCT02299544)
- Testing
- BlueWind Medical system
- Where
- 6 sites in Netherlands, United Kingdom
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- BlueWind Medical
High-risk Non-muscle Invasive Bladder Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
Researchers are looking for new ways to treat high-risk non muscle invasive bladder cancer (HR NMIBC). NMIBC is cancer in the tissue that lines the inside of the bladder but has not spread to the bladder muscle or outside of the…
- Trial name
- NCT03711032
- Testing
- Pembrolizumab, BCG
- Where
- 209 sites in United States, Australia and 28 more
- Volunteers
- 1,397 people
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder
A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013)
This study will investigate the pharmacokinetics of a single oral dose of vibegron (MK-4618) administered to participants with moderate hepatic insufficiency and healthy participants matched for age, gender, and body mass index…
- Trial name
- NCT01737684
- Testing
- Vibegron
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Overactive Bladder (OAB)
Evaluate the Safety and Efficacy of TRG-200 KIT in Patients With Refractory Overactive Bladder.
This is an open-label, single-center pilot study designed to evaluate the safety, tolerability, and preliminary efficacy of TRG-200 KIT, an intravesical sustained-release oxybutynin formulation, in adult patients with refractory…
- Trial name
- NCT07391878
- Testing
- TRG-200 KIT
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Trigone Pharma Ltd.
Bladder Cancer
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Ascending Doses of APL-1501 Extended Release (ER) Capsules Compared to APL-1202 Immediate Release (IR) Tablets in Healthy Volunteers
This is an integrated Phase 1, single centre, 2-part, open-label, dose-escalation study conducted in healthy volunteers to assess the safety, tolerability, and PK of APL-1501 ER capsules in comparison to APL-1202 IR tablets.
- Trial name
- NCT06034015
- Testing
- APL-1202 and APL-1501 (Single ascending dose), APL-1202 and APL-1501 (Multiple Ascending dose)
- Where
- Australia
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Jiangsu Yahong Meditech Co., Ltd aka Asieris
Solid Tumors
Dose Escalation of RMC-5552 Monotherapy in Relapsed/Refractory Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic (PK), and pharmacodynamic (PD) profiles of escalating doses of RMC-5552 monotherapy in adult participants with relapsed/refractory solid tumors…
- Trial name
- NCT04774952
- Testing
- RMC-5552
- Where
- 8 sites in United States
- Volunteers
- 58 people
- Sponsor
- Revolution Medicines, Inc.
Overactive Bladder, Urinary Incontinence
Long Term Follow-up Study of Safety and Efficacy of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence
The purpose of this study is to assess the long term safety and effectiveness of botulinum toxin type A in treating patients with idiopathic overactive bladder with urinary incontinence.
- Trial name
- NCT00915525
- Testing
- botulinum toxin Type A
- Where
- 8 sites in United States, Belgium and 6 more
- Volunteers
- 829 people
- Sponsor
- Allergan
Underactive Bladder
A Study of ASP8302 in Participants With Underactive Bladder
The study objectives of this study are to evaluate the efficacy of ASP8302 compared with placebo in participants with underactive bladder (UAB), to investigate the safety and tolerability of ASP8302 compared with placebo in…
- Trial name
- NCT03702777
- Testing
- ASP8302
- Where
- 29 sites in Germany, Japan and 4 more
- Volunteers
- 135 people
- Sponsor
- Astellas Pharma Europe B.V.
Overactive Bladder
A Study to Test the Effects of Tolterodine Tartrate in Patients With Overactive Bladder (0000-107)
This study will design an alternative urodynamic platform to better evaluate treatment effects of medications for overactive bladder. Part II is dependent on results of Part I and may not be conducted.
- Trial name
- NCT00768521
- Testing
- tolterodine tartrate
- Volunteers
- 20 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Cell Carcinoma (RCC), Urothelial Carcinoma
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
This is a Phase 1b/2, open-label, multicenter study of DSP-7888 Dosing Emulsion in combination with checkpoint inhibitors (nivolumab or pembrolizumab) in adult patients with solid tumors, that consists of 2 parts: dose search…
- Conditions
- Renal Cell Carcinoma (RCC), Urothelial Carcinoma, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer (PROC)
- Trial name
- NCT03311334
- Testing
- DSP-7888 Dosing Emulsion, Nivolumab, Pembrolizumab
- Where
- 19 sites in United States, Canada
- Volunteers
- 47 people
- Sponsor
- Sumitomo Pharma America, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.